Project Grant R41AG092063
Award Date 8/20/25
Completion Date 8/19/26
Dollars Obligated $499K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $804,450 Project Grant to the J. David Gladstone Institutes in San Francisco, CA. This grant, awarded on June 1, 2025, will fund a research project titled "Targeting NELL2 and GABAergic Dysfunction to Mitigate APOE4-Driven Pathogenesis in Alzheimer's Disease." The project aims to investigate the role of the APOE4 gene and its interaction with sex and aging in contributing to...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded Aivocode, Inc. a $1,244,775 project grant to develop single domain antibodies targeting Connective Tissue Growth Factor (CTGF) for improving vascular dysfunction in Alzheimer's disease. The award period runs from September 2025 to May 2027. The funding will support preclinical research to test these single domain antibodies in mouse models of Alzheimer's disease, with the goal of...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $9,781,240 Project Grant to the Institute For Molecular Medicine Inc. in California. The grant funds a multicenter Phase 1 clinical trial to evaluate the safety and immunogenicity of a preventive tau vaccine, AV-1980R/A, in cognitively unimpaired individuals at risk of Alzheimer's disease (preclinical stage). The project aims to develop an innovative immunotherapy approach for...
- This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
- This Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The goal of the project is to test whether a new humanized monoclonal antibody (ADWA11) can restore microglia-astrocyte responses as a therapy for Alzheimer's disease (AD). The $254,896 award to Glial Therapeutics, LLC will support research to understand how pharmacological inhibition of the ITGB8 integrin can modulate microglia phenotype and function to...
- The National Institute on Aging (NIA) awarded a $341,000 Project Grant (CFDA 93.866 - Aging Research) to The Roskamp Institute, Inc. in Sarasota, FL. The grant will support research to investigate the impact of the APOE4 genotype, a major genetic risk factor for Alzheimer's disease, on brain bioenergetics. The goal is to examine how APOE4-mediated disturbances in fatty acid metabolism and energy substrate availability within the cerebrovascular system and astrocytes contribute to neuronal energy...
- The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
- This Project Grant award of $751,442 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize and preclinically evaluate a brain-permeable CRISPR-based therapy to edit the APOE4 gene and convert it to the benign APOE3 variant in Alzheimer's disease (AD) models. The key products and services to be delivered include: Optimizing the CRISPR delivery platform using microfluidic synthetic exosomes (SE) to enhance plasma half-life and blood-brain barrier...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $412,500 Project Grant to the University of South Florida to investigate changes in the brain extracellular matrix during normal aging and in Alzheimer's disease. The 2-year grant, which runs from Jun 1, 2025 to May 31, 2027, aims to establish region-specific extracellular matrix composition in mouse brains, elucidate changes during normal aging, and characterize temporal and spatial...